858 Therapeutics
Dr. Schraga Schwartz is currently Principal Investigator and Robert Edward and Roselyn Rich Manson Career Development Chair in the Department of Molecular Genetics at the Weizmann Institute of Science. His lab focuses on deciphering the roles played by post-transcriptional modifications on RNA, and his work has pioneered approaches for genome-wide detection, quantification, functional interrogation and mechanistic dissection of mRNA modifications. His lab developed genome-wide approaches for interrogating m6A (Nature, 2012; Cell, 2013; Cell, 2019; Nature Methods, 2021), pseudouridine (Cell, 2014), m1A (Nature, 2017) and cytidine acetylation (Nature, 2020), uncovering roles of these modifications in diverse processes, including translational control and thermostabilization.
Prior to his appointment at the Weizmann Institute Dr. Schwartz spent four years as a postdoctoral fellow at the Broad Institute under the joint supervision of Aviv Regev and Eric Lander.
Schraga Schwartz received European Research Council Starting (2016) and Consolidator (2020) grants, a Krill Prize for Excellence in Scientific Research (2020), and the RNA Society Early Career Research Award (2020).
This person is not in the org chart
This person is not in any offices
858 Therapeutics
858 Therapeutics is a biotechnology and drug discovery company developing a portfolio of small molecule drugs that act on novel therapeutic targets in oncology, including proteins that regulate RNA and the innate immune response.